Clinical trials: Female Pattern Baldness
Androgenetic Alopecia
A Phase 2 Study to Evaluate the Safety and Efficacy of CKD-498 in Female Patients With Androgenetic Alopecia
This is a multi-centers, randomized, double-blind, parallel-group, Phase 2 Trial to evaluate the efficacy and safety of CKD-498 in female patients with Androgenetic Alopecia
- Trial name
- NCT05677438
- Testing
- CKD-498 dose#1, CKD-498 dose#2, CKD-498 dose#3
- Where
- South Korea
- Volunteers
- 121 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Female Pattern Hair Loss, Female Pattern Hair Loss, Androgenic Alopecia
Oral Minoxidil With or Without a Multifactorial Drinkable Nutraceutical in Female Pattern Hair Loss: a Retrospective Study
This retrospective observational study evaluates the outcomes of a multifactorial drinkable nutraceutical combined with oral minoxidil, compared with oral minoxidil monotherapy, in women with female pattern hair loss (FPHL)…
- Trial name
- NCT07862374
- Testing
- Oral low-dose Minoxidil, Drinkable multifactorial food supplement containing vitamins, minerals, plant extracts, and other bioactive compounds, formulated to support hair growth and scalp health in women.
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Olistic Research Labs S.L.
Androgenetic Alopecia
Efficacy and Safety of 5% Minoxidil Foam in Female Androgenetic Alopecia
The primary objective of this study is to evaluate the efficacy of once-daily 5% minoxidil foam versus placebo in female androgenetic alopecia, using the Target Area Terminal Hair Count (TAHC) as the primary endpoint.
- Trial name
- NCT07080931
- Testing
- 5% minoxidil foam
- Where
- China
- Volunteers
- 294 people
- Sponsor
- Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.
Signs of Androgenisation in Women, e.g. Hirsutism, Androgenetic Alopecia, Acne and Seborrhea, Hypersexuality in Men
A Study to Learn About the Awareness and Knowledge That Doctors Have About the Safety and Safe Use Information for Androcur and Other Cyproterone Acetate Treatments in Europe
Androcur is a type of treatment called cyproterone acetate (CPA). Androcur and other CPA treatments work by blocking a group of male sex hormones called androgens in the body.
- Conditions
- Signs of Androgenisation in Women, e.g. Hirsutism, Androgenetic Alopecia, Acne and Seborrhea, Hypersexuality in Men, Sexual Deviations in Men, Prostate Cancer
- Trial name
- Safe-CAM (NCT04925180)
- Testing
- Cyproterone Acetate (Androcur, BAY94-8367)
- Where
- 5 sites in France, Germany and 3 more
- Volunteers
- 600 people
- Sponsor
- Bayer
Androgenetic Alopecia, Female Pattern Baldness
Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia
The goal of this clinical trial is to learn about oral minoxidil 1mg in the treatment of women with androgenetic alopecia, a type of hormone-imbalanced hair loss.
- Trial name
- NCT05888922
- Testing
- Minoxidil Tablets, Minoxidil Topical, Vehicle solution
- Where
- 27 sites in Germany, Italy and 2 more
- Volunteers
- 520 people
- Sponsor
- Industrial Farmacéutica Cantabria, S.A.
Androgenetic Alopecia, Male Pattern Baldness
A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004542)
The purpose of the the study is to evaluate the ability of injections of Ji Gami(TM) C to induce hair growth in male and female subjects with hair loss.
- Conditions
- Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
- Trial name
- NCT01451151
- Testing
- Autologous cultured dermal and epidermal cells
- Where
- 2 sites in United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Aderans Research Institute
Androgenetic Alopecia, Male Pattern Baldness
A Study to Evaluate and Compare Injections of Autologous Dermal Cells Into the Balding Scalp of Subjects With Hair Loss
Evaluate the ability of Ji Gami(TM) DO to induce hair growth in male and female subjects with hair loss.
- Conditions
- Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
- Trial name
- NCT01451099
- Testing
- Autologous cultured dermal cells
- Where
- 6 sites in United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Aderans Research Institute
Androgenetic Alopecia, AGA
Safety and Efficacy of VDPHL01 in Males and Females With AGA
This study will evaluate the safety and efficacy of VDPHL01 in male and female subjects with Androgenetic Alopecia (AGA). AGA (or pattern of hair loss) is a genetic disorder caused by an excessive (too much) hair follicle…
- Conditions
- Androgenetic Alopecia, AGA, Male Pattern Baldness
- Trial name
- NCT06527365
- Testing
- VDPHL01
- Where
- 4 sites in United States
- Volunteers
- 70 people
- Sponsor
- Veradermics, Inc.
Early Female Pattern Hair Loss (FPHL)
Efficacy and Safety Evaluation of a Nutraceutical Supplement for Hair Growth, Hair Loss and Skin Improvement in Human Volunteers
The purpose of this clinical trial is to evaluate the efficacy and safety of Olistic Next Women, a nutraceutical supplement, in women diagnosed with early FPHL.This 6-month, open-label, interventional clinical trial investigates…
- Trial name
- NCT07300228
- Testing
- Drinkable multifactorial food supplement containing vitamins, minerals, amino acids, plant extracts, and other bioactive compounds, formulated to support hair growth and scalp health in women +50.
- Where
- Spain
- Volunteers
- 39 people
- Sponsor
- Olistic Research Labs S.L.
Hair Care, Hair Loss
Olistic_2025 for Hair Loss, Hair Growth, and Skin Improvement
The goal of this randomized, double-blind, placebo-controlled clinical trial is to find out whether daily oral intake of the nutraceutical Olistic Next Women can reduce hair loss, improve hair growth and quality, and improve…
- Conditions
- Hair Care, Hair Loss, Female Pattern Hair Loss
- Trial name
- NCT07300813
- Testing
- Olistic Next Women
- Where
- Spain
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Bionos Biotech S.L.
Alopecia
To Evaluate Safety and Efficacy of KX-826 in Chinese Female Subjects With Androgenetic Alopecia
This was a multi-center, randomized, double-blind, placebo-controlled Phase II clinical study of KX-826 Tincture in Chinese adult female subjects with AGA.
- Trial name
- NCT06409650
- Testing
- KX-826 dosed at 2.5mg, KX-826 dosed at 5 mg
- Where
- 15 sites in China
- Volunteers
- 160 people
- Sponsor
- Suzhou Koshine Biomedica, Inc.
Androgenetic Alopecia
A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution
Open label study to assess safety, tolerability, and efficacy of ATI-50002 in male and female subjects with androgenetic alopecia.
- Trial name
- NCT03495817
- Testing
- ATI-50002
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- Aclaris Therapeutics, Inc.
Female Pattern Baldness, Hair Loss
ENERGI-F701 for Female Hair Loss Treatment
The objective of this study is to evaluate the efficacy and safety of ENERGI-F701 Solution in female subjects with hair loss.
- Conditions
- Female Pattern Baldness, Hair Loss, Alopecia
- Trial name
- NCT03351322
- Testing
- ENERGI-F701, Regaine
- Where
- Taiwan
- Volunteers
- 67 people
- Sponsor
- Energenesis Biomedical Co., Ltd.
Androgenetic Alopecia
24 Week Clinical Trial to Evaluate Safety and Effectiveness of a Hair Growth System to Treat Male and Female Baldness
The purpose of this study is to evaluate the effectiveness of the iRestore Hair Rejuvenation System when used as directed in promoting hair growth in men and women with androgenetic alopecia
- Trial name
- NCT01686295
- Testing
- iRestore Hair Rejuvenation System
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Freedom Laser Therapy, Inc.
Androgenetic Alopecia (AGA), Androgenetic Alopecia
Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)
This study will evaluate the safety and efficacy of VDPHL01 in female subjects with Androgenetic Alopecia (AGA). AGA is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormones) that…
- Conditions
- Androgenetic Alopecia (AGA), Androgenetic Alopecia, AGA, Female Androgenetic Alopecia
- Trial name
- NCT07146022
- Testing
- VDPHL01 QD, VDPHL01 BID
- Where
- 71 sites in United States
- Volunteers
- 552 people
- Sponsor
- Veradermics, Inc.
Androgenetic Alopecia
Plasma Rich in Growth Factors (PRGF-Endoret)in the Treatment of Androgenetic Alopecia
Androgenetic alopecia (AGA) or common baldness is the most common cause of hair loss in both men and women and is caused by the action of androgens in genetically predisposed individuals.
- Trial name
- NCT01885676
- Testing
- PRGF-Endoret, Saline Solution
- Where
- 2 sites in Spain
- Sponsor
- Biotechnology Institute IMASD